Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Future work may need to assess whether extended hospital stays improve surgical care outcomes during disasters, according to one of the study authors.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.

Multidisciplinary approaches, RNA-based next-generation sequencing, and patient-specific front-line treatment decisions are all important for curating effective NSCLC treatments.